NextCell reports delay in ProTrans-Young study results

NextCell Pharma AB announced today that the reporting of topline results from its ProTrans-Young clinical trial is delayed. The company stated that the extended timeline is due to final administrative processing and sign-off of study data taking longer than planned.

The company emphasized that the delay is not related to the outcome of the study itself. The data are currently being handled by statisticians at Uppsala Clinical Research Center (UCR). ProTrans-Young is an investigator-initiated study sponsored by Uppsala University, with Professor Per-Ola Carlsson serving as the Principal Investigator.

The study has included a specified number of participants and aims to evaluate the efficacy and safety of a particular treatment. NextCell has not provided a revised timeline for when the results are expected to be announced.

NextCell Pharma AB is focused on developing cell therapies for rare diseases.